PPT-Module 6: Prostate Cancer

Victoria Sinibaldi RN MS CS CANP BC Daniel P Petrylak MD Disclosures for Ms Sinibaldi No financial interests or affiliations to disclose Disclosures for Dr Petrylak Consulting Agreements. Matthew D. Katz, M.D.. Assistant Professor. Urologic Oncology . Robotic and Laparoscopic Surgery. University of Arkansas for Medical Sciences. Winthrop P. Rockefeller Cancer Center. Anatomy Genitourinary System. Norm D. Smith, M.D.. Associate Professor. Co-Director. Urologic Oncology. University of Chicago. United States Preventive Services Task Force (USPSTF). USPSTF Warns Against Blood Test For Prostate Cancer. . Julian Mander . RPH Urology. David Anderson, Bruce Golden, Ed Wasil, Howard Zhang. 1. INFORMS Healthcare 6/24/2013. The NCI estimates that 15% of men born today will be diagnosed with prostate cancer. Average costs of $10,000 in the first year after diagnosis. David Anderson, Bruce Golden, Ed Wasil, Howard Zhang. 1. INFORMS Annual Meeting October, 2013. The NCI estimates that 15% of men born today will be diagnosed with prostate cancer. Average costs of $10,000 in the first year after diagnosis. David Anderson, Bruce Golden, Ed Wasil, Howard Zhang. 1. INFORMS Annual Meeting October, 2013. The NCI estimates that 15% of men born today will be diagnosed with prostate cancer. Average costs of $10,000 in the first year after diagnosis. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a . The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. The prostate is a gland the size of a walnut it sits at the neck of the bladder. Only men have a prostate gland!. Prostate cancer is the commonest type of male cancer . By far the biggest risk factor is age . 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . If you decide not to get screened, you can always change your mind later. If you decide to get screened, it does not mean you have to go to the next step. You should discuss each step with your docto Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening..